Background-Fibrin fragment D-dimer, one of several peptides produced when crosslinked fibrin is degraded by plasmin, is the most widely used clinical marker of activated blood coagulation. To identity genetic loci influencing D-dimer levels, we performed the first large-scale, genome-wide association search. Methods and Results-A genome-wide investigation of the genomic correlates of plasma D-dimer levels was conducted among 21 052 European-ancestry adults. Plasma levels of D-dimer were measured independently in each of 13 cohorts.
Background-Fibrin fragment D-dimer, one of several peptides produced when crosslinked fibrin is degraded by plasmin, is the most widely used clinical marker of activated blood coagulation. To identity genetic loci influencing D-dimer levels, we performed the first large-scale, genome-wide association search. Methods and Results-A genome-wide investigation of the genomic correlates of plasma D-dimer levels was conducted among 21 052 European-ancestry adults. Plasma levels of D-dimer were measured independently in each of 13 cohorts.
Each study analyzed the association between Ϸ2.6 million genotyped and imputed variants across the 22 autosomal chromosomes and natural-log-transformed D-dimer levels using linear regression in additive genetic models adjusted for age and sex. Among all variants, 74 exceeded the genome-wide significance threshold and marked 3 regions. At 1p22, rs12029080 (Pϭ6.4ϫ10 Ϫ52 ) was 46.0 kb upstream from F3, coagulation factor III (tissue factor). At 1q24, rs6687813 (Pϭ2.4ϫ10 Ϫ14 ) was 79.7 kb downstream of F5, coagulation factor V. At 4q32, rs13109457 (Pϭ2.9ϫ10 Ϫ18 ) was located between 2 fibrinogen genes: 10.4 kb downstream from FGG and 3.0 kb upstream from FGA. Variants were associated with a 0.099-, 0.096-, and 0.061-unit difference, respectively, in natural-log-transformed D-dimer and together accounted for 1.8% of the total variance. When adjusted for nonsynonymous substitutions in F5 and FGA loci known to be associated with D-dimer levels, there was no evidence of an additional association at either locus. Conclusions-Three genes were associated with fibrin D-dimer levels. Of these 3, the F3 association was the strongest, and has not been previously reported. (Circulation. 2011;123:1864-1872.)
Key Words: epidemiology Ⅲ fibrin fragment D Ⅲ genome-wide association study Ⅲ hemostasis Ⅲ meta-analysis Ⅲ thrombosis F ibrin fragment D-dimer is one of several peptides produced when crosslinked fibrin is degraded by plasmin. The amount of D-dimer in plasma is of scientific interest. Several assays of D-dimer have demonstrated their clinical usefulness in determining noninvasively the likelihood of clinically suspected venous thrombosis and pulmonary embolism. 1,2 D-dimer levels have also been associated with the risks of subsequent arterial and venous thrombotic events in middle-aged and older adults. [3] [4] [5] [6] [7] [8] [9] [10] 
Clinical Perspective on p 1872
Estimates of the heritability of plasma D-dimer levels range from 23% to 65% in Northern Europeans. [11] [12] [13] Several genetic predictors of D-dimer levels have been previously reported. A 2008 publication clearly identified the association of variation within the fibrinogen gene cluster, particularly FGA and FGG, with D-dimer levels. 14 There was also evidence of an association with genetic variation in 2 other fibrinolysis-related genes, urokinase plasminogen activator (PLAU) and plasminogen activator inhibitor 1 (SERPINE1). In other studies, the factor V Leiden variant (rs6025, 1691 GϾA) and the factor II 20210A variant (rs1799963, GϾA) have both been associated with D-dimer levels. 8 Although genetic influences beyond genes in the clotting cascade have been proposed, none have been identified. 15 The aim of this study was to identify areas of the genome that are statistically associated with plasma levels of fibrin D-dimer. To date, no large-scale genome-wide investigation of the genomic correlates of D-dimer plasma levels has been published. Using data from 21 052 European-ancestry adults, we investigated genome-wide associations between common genetic variation and plasma levels of D-dimer.
Methods

Setting
The meta-analysis was conducted in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, which includes data from several prospective, population-based cohorts of adults in the United States and Europe. 16 TwinsUK; and the CROATIA-Vis study. These studies have been described elsewhere. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] 
Subjects
Eligible participants for these analyses had a D-dimer measure and high-quality data from the genome-wide scans (see below), and were not using a coumarin-based anticoagulant at the time of the phenotype measurement. Participants were of European ancestry by self-report. Each study received institutional review board or ethics approval, and all participants provided written informed consent for the use of their DNA in research.
Measures
D-Dimer
Plasma measures of D-dimer were obtained at the time of cohort entry for CHS, CROATIA-Vis, KORA-F3, ORCADES, PROSPER, RS, and TwinsUK and at a follow-up visit for B58C (2002 and 2003 examinations), FHS (examination cycle 5, 1991 to 1995), LBC1921 (wave 3 in 2007 to 2008), and LBC1936 (wave 2 from 2007 to 2010). The D-dimer phenotype was measured by ELISA using monoclonal antibodies in a kit or prepared in the laboratory: ELISA assay (Hyphen, Paris, France) in B58C, CROATIA-Vis, and ORCADES 17 ; VIDAS D-dimer (bioMérieux, Marcy Etoile, France) in LBC1921 and LBC1936 (nϭ391) 18 ; ELISA HemosIL D-dimer (Instrumentation Laboratory, Italy) in LBC1936 (nϭ162) 19 ; Biopool AB in PROSPER 20 ; Enzygnost D-dimer micro (Behringwerke Diagnostica, Marburg, Germany) in RS 21 ; and Biopool TintElize ELISA D-dimer (Trinity Biotech, Bary, Ireland) in TwinsUK. 22 Two monoclonal antibodies directed against nonoverlapping antigenic determinants were used to detect D-dimer from crosslinked fibrin but not D-monomer in CHS, FHS, and KORA-F3. 4, 23, 24 Baseline measures of clinical and demographic characteristics were obtained at the time of cohort entry for CHS, CROATIA-Vis, KORA-F3, ORCADES, PROSPER, RS, and TwinsUK and at the time of phenotype measurement for B58C, FHS, LBC1921, and LBC1936. Measures, taken with standardized methods as specified by each study, included in-person measures of height and weight and self-reported treatment of diabetes mellitus and prevalent cardiovascular disease (history of myocardial infarction, angina, coronary revascularization, stroke, transient ischemic attack) or venous thrombotic disease (history of deep vein thrombosis or pulmonary embolism).
Genotyping and Imputation
Genotyping was performed with DNA collected from phlebotomy from all cohorts except B58C, which used cell lines. Genome-wide assays of single-nucleotide polymorphisms (SNPs) were conducted independently in each cohort with various Affymetrix and Illumina panels ( Table I in the online-only Data Supplement). Genotype quality control and data cleaning, which included assessing Hardy-Weinberg equilibrium and variant call rates, were conducted independently by each study; details have been published elsewhere and are provided in Table I in the online-only Data Supplement. 16, 25, 26 We investigated genetic variation in the 22 autosomal chromosomes. Genotypes were coded as 0, 1, and 2, representing the number of copies of the coded alleles. Each study independently applied quality-control criteria ( Table II in the online-only Data Supplement) and imputed their genotype data to the Ϸ2.6 million SNPs derived from the HapMap white sample from the Centre d'Etude du Polymorphisme Humain using imputation software that included MACH, Bayesian Imputation Based Association Mapping, or IMPUTE. [27] [28] [29] Imputation results were summarized as an "allele dosage" defined as the expected number of copies of the minor allele at that SNP (a continuous value between 0 and 2) for each genotype. Each cohort calculated a ratio of observed to expected variance of the dosage statistic for each SNP. This value, which generally ranges from 0 to 1 (poor to excellent), reflects imputation quality.
Statistical Analyses
Investigators from all cohorts developed the prespecified analytic plan described below. Each study independently analyzed their genotype-phenotype data. All studies used linear regression to conduct association analyses between measured and imputed SNPs and natural-log-transformed D-dimer measures except for CROATIA-Vis, FHS, and ORCADES, which used a linear mixedeffects model to account for family relationships, and TwinsUK, which used a score test and variance components method as implemented in Merlin. 30 -33 An additive genetic model with 1 df was adjusted for age and sex. In addition, CHS and PROSPER adjusted for field site or center; CROATIA-Vis, FHS, and ORCADES adjusted for generation and ancestry using principal components; and B58C adjusted for nuisance blood-draw variables. 17, 34 For each analysis, a genomic control coefficient, which estimated the extent of underlying population structure on the basis of test-statistic inflation, was used to adjust standard errors. 35 Within-study findings were combined across studies to produce summary results using standard meta-analytic approaches. A fixed-effects, inverse-variance weighted meta-analysis was performed, and summary P values and ␤ coefficients were calculated. Parameter coefficient represents natural-log-transformed plasma D-dimer differences associated with a 1-unit change in allele dosage. All meta-analyses were conducted with MetABEL (http://mga.bionet.nsc.ru/ϳyurii/ABEL). For loci containing genes already known to be associated with D-dimer, we conducted secondary analyses, adjusting for Ն1 SNPs within the gene in addition to the variant with an association with D-dimer that has already been established. This allowed us to assess possible novel associations independently of previously known strong signals.
The a priori threshold of genome-wide significance was set at a value of Pϭ5.0ϫ10 Ϫ8 . When Ͼ1 SNP clustered at a locus, we chose the SNP with the smallest P value to represent the locus. The amount of variation explained by the top SNPs was the difference in the r 2 value when comparing a model containing only the adjustment variables, age, sex, and study-design variables with a model also containing top genome-wide significant SNPs. Each study calculated the amount of variation explained, and these estimates were combined across cohorts using sample-size weighted averages. We also identified subthreshold loci, those marked by variants with a value of PϽ1.0ϫ10 Ϫ5 but greater than the level of genome-wide significance. We limited our report to those subthreshold loci at a distance of Ն200 kb from other reported loci.
Results
A total of 21 052 participants of European ancestry were eligible from the 13 studies. Counts of participants and their characteristics are provided in Table 1 . The average age in each cohort ranged from 44.9 to 86.6 years, and 43% of the participants were men. Summary statistics for the untrans- formed and natural-log-transformed D-dimer phenotype are also listed in Table 1 .
Within the 13 cohorts, the genomic control coefficients were small (Ͻ1.036), suggesting negligible test statistic inflation. The Figure presents all 2 522 393 meta-analysis P values organized by chromosome and genomic position. Among these variants, 74 exceeded the genome-wide significance threshold and marked 3 regions on 2 chromosomes: 1p22, 1q24, and 4q32. Table 2 lists the top variant for each chromosomal region. The amount of variance in the natural-log-transformed 
The genome-wide log 10 P value plots of D-dimer for the 2 522 393 single-nucleotide polymorphisms meta-analyzed. The horizontal line marks the 5.0ϫ10 Ϫ8 P value threshold of genome-wide significance.
D-dimer phenotype explained by the top 3 genetic variants was 1.8% across the 13 cohorts (range, 0% to 4.2%).
We identified genome-wide significant signals at chromosomal position 1p22 ( Figure I in the online-only Data Supplement). Rs12029080 was associated with the smallest P value in this region (Pϭ6.4ϫ10 Ϫ52 ; minor allele fre-quencyϭ0.305) and was 46.0 kb upstream from F3, coagulation factor III, also known as tissue factor. Each copy of the G allele was associated with a 0.099-unit (genome-wide significance confidence interval [CI], 0.064 to 0.134) increase in the natural-log-transformed D-dimer (ng/dL) or a 10.4% (CI, 6.6 to 14.3) increase in median D-dimer level. A forest plot of the meta-analyzed studies is depicted in Figure II in the online-only Data Supplement.
A second genome-wide significant locus on chromosome 1 was found at 1q24 ( Figure III in the online-only Data Supplement). Rs6687813 was associated with the smallest P value at this locus (Pϭ2.4ϫ10 Ϫ14 ; minor allele fre-quencyϭ0.059). Each copy of the A allele was associated with a 0.096-unit (CI, 0.027 to 0.165) increase in the natural log of D-dimer or a 10.1% (CI, 2.7 to 17.9) increase in median D-dimer level. A forest plot of the meta-analyzed studies is depicted in Figure IV in the online-only Data Supplement. This SNP was located 79.7 kb downstream of F5, coagulation factor V. The rs6687813 variant is one of several weak proxies for the F5 Leiden R506Q (rs6025) variant (r 2 ϭ0.12, D=ϭ1.0). In a subset of 5 cohorts in which the F5 Leiden variant was genotyped (B58C-WTCCC, CHS, CROATIA-Vis, ORCADES, and RS), we reanalyzed the data from chromosome 1 and adjusted for rs6687813 and rs6025 to estimate the amount of variation explained independently by each SNP. The P value for rs6687813 decreased from 2.5ϫ10 Ϫ5 to 4.4ϫ10 Ϫ2 when also adjusted for rs6025, and was no longer significantly associated with the phenotype. In the subset of cohorts, the F5 R506Q (rs6025) variant was associated with a 0.22-unit (CI, 0.013 to 0.419) increase in natural-log-transformed D-dimer (Pϭ6.4ϫ10 Ϫ9 ) or a 24% (CI, 1.3 to 52.0) increase in median D-dimer level. A forest plot of rs6025 is provided in Figure V in the online-only Data Supplement.
A third genome-wide significant locus was identified at chromosomal position 4q32 ( Figure VI in the online-only Data Supplement). Rs13109457 had the smallest P value (Pϭ2.9ϫ10 Ϫ18 ; minor allele frequencyϭ0.250) and was located between 2 fibrinogen genes: 10.4 kb downstream from FGG, fibrinogen ␥ chain, and 3.0 kb upstream from FGA, fibrinogen ␣ chain. Each copy of the A allele was associated with a 0.061-unit (CI, 0.023 to 0.099) increase in the natural log of D-dimer or a 6.3% (CI, 2.3 to 10.4) increase in median D-dimer level. A forest plot of the meta-analyzed studies is depicted in Figure VII in the online-only Data Supplement. The rs13109457 variant is in strong linkage disequilibrium with rs6050 (r 2 ϭ0.96, D=ϭ1.0), which codes a missense substitution at amino acid site 331 (Thr to Ala) in FGA. The rs6050 SNP was associated with a value of Pϭ1.8ϫ10 Ϫ17 , and each additional risk allele of rs6050 was associated with a 0.06-unit (CI, 0.022 to 0.098) increase in natural-log-transformed plasma D-dimer or a 6.3% (CI, 2.3 to 10.4) increase in median D-dimer level. When we adjusted for age, sex, and the Thr331Ala variant, D-dimer levels were no longer associated with rs13109457 (Pϭ8.1ϫ10 Ϫ1 ).
An additional 13 loci across 8 chromosomes had Ն1 variants with a P value that did not exceed the threshold of genome-wide significance (Pϭ5.0ϫ10 Ϫ8 ), but was smaller than 1.0ϫ10 Ϫ5 . Details for these 13 loci, including closest reference gene, are presented in Table II in the online-only Data Supplement.
Discussion
A genome-wide investigation of the plasma fibrin D-dimer phenotype in Ͼ20 000 adults of European ancestry yielded 3 loci that exceeded the threshold of significance. All 3 loci were associated with genes previously known to be involved in the coagulation cascade: F3, F5, and FGA. The association of genetic variation in F3 with D-dimer is novel and has not been previously reported. The associations with F5 and FGA replicate previous findings.
Genome-Wide Significant Associations
The F3 locus, also known as tissue factor or thromboplastin, was associated with the smallest P values, and was located in the presumed regulatory region of F3, Ϸ46.0 kb upstream from the start of transcription. The variant with the smallest P value, rs12029080, was common, and was among 29 SNPs that reached genome-wide significance within a region that spanned 48 kb. Although very highly significant, its association with an increase in plasma levels of D-dimer was modest. The activated serine protease, factor VIIa, bound to SNP indicates single-nucleotide polymorphism; MAF, weighted minor allele frequency; and CI, confidence interval based on a 2-sided ␣ϭ0.00000005. *Parameter coefficient represents the change associated with a 1-unit change in allele dosage. †Estimated percentage the change in median D-dimer associated with a 1-unit change in allele dosage. ‡R 2 value for quality of measurement Ͼ0.90. §R 2 value for quality of measurement Ͼ0.85. its cofactor, tissue factor produced by F3, initiates the activation of the extrinsic coagulation pathway. There has been no prior report of genetic variation in or upstream from F3 affecting levels of D-dimer, and there are no known direct roles of tissue factor, the protein product of F3, on fibrin degradation. It is presumed that F3 modulates D-dimer through the initiation of the extrinsic pathway, which leads to changes in coagulation and a subsequent modification of fibrinolysis and a change in the amount of D-dimer fragments shed. There is increasing interest in the roles of tissue factor in the initiation of hemostasis, arterial and venous thrombosis, inflammation, and tumor growth and metastasis. 36 The variants with the smallest P values tagging the F5 and FGA loci were immediately downstream and upstream, respectively, from the start sites of transcription. When adjusted for 2 nonsynonymous variants known to be associated with D-dimer levels, the F5 R506Q variant (rs6025) and the FGA Thr331Ala variant (rs6050), there was no longer strong evidence of an association of D-dimer levels with top SNPs at either locus; it was concluded that the rs6025 and rs6050 variants, which produce a prothrombotic environment by increasing resistance to activated protein C and by producing stiffer, more intensively crosslinked clots, respectively, likely accounted for the observed genetic signal. [37] [38] [39] 
Relevance for Cardiovascular Disease and Cardiovascular Outcomes
Activation of blood coagulation plays a key role in hemostasis and in arterial and venous thrombosis (see Figure IV in the online-only Data Supplement). Fibrin D-dimer is the most widely used clinical marker of activated blood coagulation. Epidemiological and clinical studies over the last 20 years have established its associations with risks of arterial and venous thromboembolic events and with other pathologies, including disseminated intravascular coagulation, cancer progression, and cognitive decline. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 20, 40 The present study confirms a previous report from a smaller study that D-dimer levels are associated with the factor V Leiden F5 R506Q variant (rs6025), which is associated with risks of arterial and venous thrombosis. 8, 41 Also confirmed is a previous report that D-dimer levels are associated with the FGA Thr331Ala variant (rs6050) variant, which is also associated with risks of arterial and venous thrombosis. 14, 42, 43 However, the most important finding in this report is the novel association of D-dimer levels with variation upstream from F3, which produces tissue factor. Although there is considerable experimental evidence that tissue factor plays an important role in the initiation of hemostasis and arterial thrombosis, there has been very limited epidemiological evidence to date that tissue factor initiates activation of blood coagulation in generally healthy individuals. 36 Our demonstration that a genetic variant upstream from F3 is associated with variation in D-dimer levels in generally healthy populations supports the concept that F3 might be a potential therapeutic target to reduce thrombotic risk. 36 The measurement of plasma D-dimer has clinical utility when ruling out a pulmonary embolism diagnosis in the acute phase for symptomatic patients, but is otherwise a weak predictor of the risk of arterial and venous thrombotic events in healthy persons. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The overall genetic contribution of the 3 loci to D-dimer variation identified in this report was modest, Ͻ2% of variation in the phenotype, and is unlikely to have immediate applications to clinical prediction models for arterial or venous thrombosis in the general population.
Subthreshold Associations
Among the 13 subthreshold loci identified, 7 had high-signal markers in genes and another 3 had markers within 50 kb of genes. Among the 7 were 2 related to coagulation phenotypes, the ABO blood group (ABO) and the endothelial protein C receptor (PROCR). Larger sample sizes are necessary to identify whether there are genome-wide significant associations with these 13 loci.
Strengths and Limitations
This is the first genome-wide association study to attempt to discover novel genetic associations with plasma fibrin D-dimer levels. The meta-analysis included Ͼ20 000 individuals of European ancestry and examined Ͼ2.5 million markers spread throughout the genome. The novel association identified was for a variant with a P value that was Ͼ40 orders of magnitude smaller than the significance threshold of 5.0ϫ10 Ϫ8 set as significant. Genetic associations of such strength have consistently been replicated in other settings; for this reason, we did not seek replication. 44 -46 With a sample size of Ϸ21 000, we had 80% power (2-sided ␣ϭ5.0ϫ10 Ϫ8 ) to detect a 0.067-unit difference in log D-dimer (meanϭ5, SDϭ1) for a variant with a minor allele frequency of 0.3. Most of the subthreshold findings had smaller differences in log D-dimer levels than the 0.067 difference. The D-dimer phenotype was measured in a standardized fashion within each cohort, but measurement methods differed between cohorts and likely introduced betweengroup variability. 40 This variability may decrease statistical power to find associations of smaller magnitudes. Not all SNPs tested were directly genotyped, and the imputation quality varied across SNPs and cohorts. For poorly imputed SNPs, there was reduced statistical power to detect an association. For each identified locus, we chose the SNP with the smallest P value, but the causal variant-if one existsneed not be the one with the smallest P value or may not have been measured or imputed. There was variability in the cohort-specific point estimates around the meta-analysisestimated mean effect of each SNP. This type of variation is expected and most likely attributable to random variation in the genotype-phenotype association but may also be influenced by other unmeasured factors.
Conclusions
Using data from 13 cohorts that included 21 052 participants, we identified 3 genes associated with fibrin D-dimer levels (F3, F5, and FGA) , of which the F3 association has not been previously reported. The proportion of variation in D-dimer explained by these variants was modest and, although unlikely to be useful for clinical prediction, should provide further insights into the molecular pathways underlying activation of blood coagulation and possibly subsequent fibrinolysis.
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